PI3K inhibitor
Showing 26 - 50 of >10,000
Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)
Recruiting
- Chronic Lymphocytic Leukemia
- +6 more
- Copanlisib
- Nivolumab
-
Duarte, California
- +2 more
Mar 9, 2022
Refractory/Recurrent Primary CNS Lymphoma (PCNSL) Trial in United States (Ibrutinib, Copanlisib)
Recruiting
- Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
-
Basking Ridge, New Jersey
- +6 more
Jul 27, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
-
Monterey, California
- +4 more
Aug 29, 2022
Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)
Recruiting
- Follicular Lymphoma
-
München, Bavaria, Germany
- +39 more
May 19, 2022
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal
Recruiting
- Platinum-Refractory Fallopian Tube Carcinoma
- +11 more
- Copanlisib Hydrochloride
- +4 more
-
Aurora, Colorado
- +2 more
Dec 8, 2022
Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin Trial in United States (duvelisib, PI3K inhibitor)
Terminated
- Lymphoma, Small Lymphocytic
- +4 more
- duvelisib
- PI3K inhibitor
-
Little Rock, Arkansas
- +10 more
Mar 15, 2021
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,
Active, not recruiting
- Estrogen Receptor Negative
- +6 more
- Biomarker Analysis
- +3 more
-
Birmingham, Alabama
- +8 more
Feb 3, 2022
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)
Terminated
- Estrogen Receptor Positive
- +16 more
- Biopsy of Breast
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022
Head and Neck Squamous Cell Carcinoma Trial (TL117, Paclitaxel)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- (no location specified)
Apr 9, 2021
Asthma Trial in Germany, United Kingdom (IPI-145, a PI3K Inhibitor, Placebo to match IPI-145)
Completed
- Asthma
- IPI-145, a PI3K Inhibitor
- Placebo to match IPI-145
-
Berlin, Germany
- +3 more
Mar 15, 2021
Carcinoma, Squamous Cell of Head and Neck Trial in France (Copanlisib, Cetuximab)
Terminated
- Carcinoma, Squamous Cell of Head and Neck
-
Angers, France
- +6 more
Mar 24, 2021
Advanced Gastric Adenocarcinoma Trial in Seoul (GSK2636771, Paclitaxel)
Completed
- Advanced Gastric Adenocarcinoma
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System, Yonsei Canc
Apr 21, 2021
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (Aliqopa, BAY80-6946))
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (Aliqopa, BAY80-6946)
-
Birmingham, Alabama
- +100 more
Feb 10, 2022
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Copanlisib
- +2 more
-
Los Angeles, California
- +4 more
Jul 19, 2022
Breast Cancer Trial in Los Angeles, Bronx (Gedatolisib, Faslodex, Palbociclib)
Active, not recruiting
- Breast Cancer
- Gedatolisib
- +3 more
-
Los Angeles, California
- +1 more
Jan 25, 2022
Glioblastoma, Adult Trial in United States (Paxalisib (GDC-0084))
Active, not recruiting
- Glioblastoma, Adult
- Paxalisib (GDC-0084)
-
Los Angeles, California
- +5 more
Aug 16, 2022
Advanced or Metastatic Breast Cancer Trial in Worldwide (MEN1611, Trastuzumab, Fulvestrant)
Active, not recruiting
- Advanced or Metastatic Breast Cancer
- MEN1611
- +2 more
-
Fort Lauderdale, Florida
- +26 more
Feb 14, 2022